Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:
- Describe the rationale for common approaches to cancer immunotherapy.
- Identify the appropriate clinical management of immune-related adverse events of immunotherapy agents.
- Implement cancer immunotherapy treatments for skin cancers, lung, genitourinary, head and neck, hematologic cancers, and/or additional solid tumors into clinical practice appropriately.
- Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.
The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2019-2020 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.
The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.